Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run?
Stanley Druckenmiller's Duquesne Family Office has 16.6% of its $5.2 billion portfolio in Natera (NTRA), making it the top holding. Natera's Q2 revenue rose 37.7% YoY to $752.8 million, driven by oncology testing. The stock has surged 80% since May 2026, but its valuation is steep at 17 times trailing sales.
How this was made
The 30-second read
Why it matters
The Q2 earnings release provides fresh quantitative data that could influence trader positioning in NTRA and related biotech stocks.
Market read
Natera's strong earnings and regulatory wins may attract buying interest, but valuation concerns could temper price moves.
What to watch
Potential reimbursement challenges and competition in liquid biopsy space could limit upside.
Background
Stanley Druckenmiller's Duquesne Family Office holds a large stake in Natera, underscoring confidence in the company's growth trajectory.
Ticker impact
Natera reported Q2 revenue of $752.8M, 37.7% YoY growth and strong oncology test volume, marking fresh earnings data.
Modest upside potential as growth continues, but high multiple may limit rally.
Strong top-line growth and new regulatory approvals support future earnings, but unprofitability and high sales multiple temper enthusiasm.
Market effects
Positive signal for genomics and molecular diagnostics sector as Natera's oncology test volumes surge.
U.S. biotech investors may see increased interest; Japanese and EU regulatory approvals could boost regional biotech sentiment.
Highlights growing demand for liquid biopsy technologies worldwide.
Counterpoint
High sales multiple and ongoing unprofitability suggest the stock may be overvalued despite growth.
Key entities
- CompanyNatera
Genomics diagnostics firm reporting Q2 results.
- InvestorStanley Druckenmiller
Billionaire investor with a sizable holding in Natera.
